Stock Track | Teva Pharmaceutical Soars 5% on Positive Study Data For Investigational IBD Drug

Stock Track12-19

Teva Pharmaceutical Industries Ltd. (TEVA) stock surged by 5% in the intraday trading session on Wednesday, driven by promising results from a mid-stage study on its investigational anti-TL1A therapy, duvakitug, for the treatment of inflammatory bowel diseases (IBD) such as Ulcerative Colitis and Crohn's disease.

The Phase 2b RELIEVE UCCD study, conducted in collaboration with Sanofi (SNY), met its primary endpoints for both diseases. For Ulcerative Colitis, up to 47.8% of patients receiving the high dose of duvakitug achieved clinical remission, compared to 20.45% for placebo. In the Crohn's disease group, up to 47.8% of patients on the high dose achieved endoscopic response, versus 13% for placebo.

Buoyed by these positive results, which analysts highlighted as exceeding investor expectations, several firms raised their price targets on Teva stock. Barclays lifted its target to $28 from $25, while UBS increased its target to $28 from $26, citing duvakitug's potential and Teva's potential sale of its active pharmaceutical ingredients business as potential catalysts for further upside in 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1146419531?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-19 01:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1146419531","market":"hk","top_or_hot":-1,"title":"Stock Track | Teva Pharmaceutical Soars 5% on Positive Study Data For Investigational IBD Drug","media":"Stock Track","content":"<p>Teva Pharmaceutical Industries Ltd. (TEVA) stock surged by 5% in the intraday trading session on Wednesday, driven by promising results from a mid-stage study on its investigational anti-TL1A therapy, duvakitug, for the treatment of inflammatory bowel diseases (IBD) such as Ulcerative Colitis and Crohn's disease.</p>\n\n<p>The Phase 2b RELIEVE UCCD study, conducted in collaboration with Sanofi (SNY), met its primary endpoints for both diseases. For Ulcerative Colitis, up to 47.8% of patients receiving the high dose of duvakitug achieved clinical remission, compared to 20.45% for placebo. In the Crohn's disease group, up to 47.8% of patients on the high dose achieved endoscopic response, versus 13% for placebo.</p>\n\n<p>Buoyed by these positive results, which analysts highlighted as exceeding investor expectations, several firms raised their price targets on Teva stock. Barclays lifted its target to $28 from $25, while UBS increased its target to $28 from $26, citing duvakitug's potential and Teva's potential sale of its active pharmaceutical ingredients business as potential catalysts for further upside in 2025.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Teva Pharmaceutical Soars 5% on Positive Study Data For Investigational IBD Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Teva Pharmaceutical Soars 5% on Positive Study Data For Investigational IBD Drug\n</h2>\n\n<h4 class=\"meta\">\n\n2024-12-19 01:39 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Teva Pharmaceutical Industries Ltd. (TEVA) stock surged by 5% in the intraday trading session on Wednesday, driven by promising results from a mid-stage study on its investigational anti-TL1A therapy,...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEVA","symbol_name":"梯瓦制药","start_time":0,"source_url":"","article_id":"1146419531","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1146419531","pubTimestamp":1734543547,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Teva Pharmaceutical Industries Ltd.  stock surged by 5% in the intraday trading session on Wednesday, driven by promising results from a mid-stage study on its investigational anti-TL1A therapy, duvakitug, for the treatment of inflammatory bowel diseases  such as Ulcerative Colitis and Crohn's disease.The Phase 2b RELIEVE UCCD study, conducted in collaboration with Sanofi , met its primary endpoints for both diseases. For Ulcerative Colitis, up to 47.8% of patients receiving the high dose of duv","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEVA":"梯瓦制药"},"translate_title":"Teva Pharmaceutical因IBD研究药物的积极研究数据而飙升5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1},"content_text":"Teva Pharmaceutical Industries Ltd. (TEVA) stock surged by 5% in the intraday trading session on Wednesday, driven by promising results from a mid-stage study on its investigational anti-TL1A therapy, duvakitug, for the treatment of inflammatory bowel diseases (IBD) such as Ulcerative Colitis and Crohn's disease.\nThe Phase 2b RELIEVE UCCD study, conducted in collaboration with Sanofi (SNY), met its primary endpoints for both diseases. For Ulcerative Colitis, up to 47.8% of patients receiving the high dose of duvakitug achieved clinical remission, compared to 20.45% for placebo. In the Crohn's disease group, up to 47.8% of patients on the high dose achieved endoscopic response, versus 13% for placebo.\nBuoyed by these positive results, which analysts highlighted as exceeding investor expectations, several firms raised their price targets on Teva stock. Barclays lifted its target to $28 from $25, while UBS increased its target to $28 from $26, citing duvakitug's potential and Teva's potential sale of its active pharmaceutical ingredients business as potential catalysts for further upside in 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1146419531"}